Tumour necrosis factor blockade and the risk of osteoporosis: back to the future.
Osteoporosis is a common clinical problem, especially in patients with rheumatoid arthritis (RA). A reduction in bone mineral density (BMD) of the axial and appendicular skeleton ranging from 7% to 15% has been reported in RA in studies employing a variety of densitometric techniques. Reports consistent with a beneficial effect of tumour necrosis factor blockade on BMD have begun to emerge in recent years, and in Arthritis Research and Therapy, a case control study reports that patients treated with infliximab for RA had preservation of BMD in the lumbar spine and femoral neck compared to those treated with methotrexate.
Sambrook
Philip
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005272:Femur Neck / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D011859:Radiography; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D050071:Bone Density Conservation Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab